health 🩺 Liver drug shows benefits before weight loss
New data suggests zabopegdutide might work directly on the liver to combat MASH. This finding comes from D&D Pharmatech in South Korea, as published in The Lancet Gastroenterology & Hepatology. In the 12-week Phase 2 study, nearly three-quarters of patients reduced liver fat by over 50%. Importantly, these improvements were seen even before patients achieved significant weight loss. This suggests the drug could offer a direct therapeutic effect beyond just weight reduction. 🩺